Initiation of sunset review investigation concerning imports of “Amoxycillin Trihydrate” originating in or exported from China PR (10.09.2021)

Product under consideration – Amoxicillin Trihydrate is a semi synthetic antibiotic, an analog of ampicillin, with a broad spectrum of bactericidal activity against many Gram-positive and Gram-negative microorganisms. The following types of products are however, excluded from the scope of the product under consideration:

  1. Amoxycillin Sodium Sterile and Flucloxacillin Sodium Sterile,
  2. Amoxicillin Trihydrate Compacted Ampicillin Trihydrate Compacted and
  3. Amoxicillin Trihydrate and Clavulanate Potassium

HS Code – 29411030.

Uses – Amoxicillin is used to reduce the development of drug-resistant bacteria. To maintain the effectiveness of Amoxicillin and other antibacterial drugs, Amoxicillin should be used only to treat infections that are proven or strongly suspected to be caused by bacteria.

Countries involved – China PR.

Applicants – M/s Aurobindo Pharma Limited

Supported by – M/s Penam Laboratories Limited and M/s Centrient Pharmaceuticals India Private Limited

Period of investigation – 1st April 2020 to 31st March, 2021

Injury period – April, 2017-March, 2018, April, 2018-March, 2019, April, 2019-March, 2020 and the POI

Past investigations involving the product – The original anti-dumping duties on imports of the product from China PR was imposed in 2017.

Facts of the present case – The Authority has found prima facie evidence of dumping by exporters from China PR into Indian market. The Authority has also found prima facie evidence of likelihood of continuation/recurrence of dumping margin and injury to the domestic industry in the event of cessation of duty considering positive dumping margin, export orientation of producers, unutilized capacities and potential trade diversion and price attractiveness of the Indian Market.